Results 71 to 80 of about 1,153,626 (336)

The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases [PDF]

, 2006
Pharmacological intervention on the immune system to achieve more intense lymphocyte responses has potential application in tumour immunology and in the treatment of chronic viral diseases. Immunostimulating monoclonal antibodies are defined as a new
Alfaro, C. (Carlos), Arina, A. (Ainhoa), Arribillaga, L. (Laura), Azpilicueta, A. (Arantza), Bendandi, M. (Maurizio), Huarte, E. (Eduardo), Lasarte, J.J. (Juan José), Melero, I. (Ignacio), Murillo, O. (Oihana), Perez-Gracia, J.L. (Jose Luis), Prieto, J. (Jesús), Tirapu, I. (Íñigo)   +11 more
core  

A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition [PDF]

, 2013
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broadly neutralizing antibodies 2F5 and 4E10. To date, no immunization regimen in animals or humans has produced HIV-1 neutralizing MPER-specific antibodies ...
Aasa-Chapman, Marlén M. I., Battella, Simone, Bonvin, Alexandre M. J. J., Davis, David, El Khattabi, Mohamed, Favier, Adrien, Forsman Quigley, Anna, Hinz, Andreas, Hock, Miriam, Hulsik, David Lutje, Langedijk, Johannes P. M., Liu, Ying-ying, Macheboeuf, Pauline, McCoy, Laura E., Poignard, Pascal, Ramos, Alejandra, Rutten, Lucy, Sabin, Charles, Seaman, Michael S., Simorre, Jean-Pierre, Strokappe, Nika M., Verrips, C. Theo, Weiss, Robin A., Weissenhorn, Winfried   +23 more
core   +6 more sources

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

Advancements in the application of reporter gene cell lines in bioactivity evaluation of biological products

Bioresources and Bioprocessing
The assessment of biological product activity is a key aspect of quality control. Currently, in vitro assays serve as the primarily method employed by both companies and regulatory agencies to evaluate biological activity.
Kaijuan Yi, Can Wang, Huili Lu
doaj   +1 more source

Therapeutic Monoclonal Antibodies

The Keio Journal of Medicine, 2011
Over a hundred years has passed since the discovery of the "magic bullet" serum therapy by Kitasato and Behring, the first ever therapeutic use of antibodies. More than 80 years later, the investigation of immunoglobulin structure and function and the development of cell and molecular biology introduced the production of monoclonal antibodies (MoAbs ...
openaire   +3 more sources

Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the a-chain of the human interleukin-2 receptor [PDF]

, 1992
The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 ...
Flieger, Dimitri, Kaluzab, Brigitte, Lenz, Helmut, Reiter, Christian, Rieber, Ernst Peter, Riethmüller, Gert, Scheuer, Werner, Schwirzke, Marina, Weidle, Ulrich H., Weiss, Elisabeth H., Weissenhorn, Winfried   +10 more
core   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Monoclonal antibodies. Basic features

Neurología (English Edition), 2011
Introduction: Monoclonal antibodies are a powerful tool in laboratory diagnosis and are increasingly used in the treatment of several diseases. Development: Antibody development and characterization has a long history and goes back to immunology itself ...
A. García Merino
doaj   +1 more source

Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system

Cardio-Oncology, 2023
Background Antineoplastic monoclonal antibodies (mAbs), such as trastuzumab, bevacizumab, and pertuzumab have been the mainstay of therapy in cancer patients.
Abdulrazaq S. Al-Jazairi, Nahlah Bahammam, Dhai Aljuaid, Lama Almutairi, Shroog Alshahrani, Norah Albuhairan, Peter M. B. Cahusac, Ghazwa B. Korayem   +7 more
doaj   +1 more source

Monoclonal Antibodies for Non-Hodgkin's Lymphoma: State of the Art and Perspectives [PDF]

, 2010
Monoclonal antibodies have been the most successful therapeutics ever brought to cancer treatment by immune technologies. The use of monoclonal antibodies in B-cell Non-Hodgkin's lymphomas (NHL) represents the greatest example of these advances, as the ...
Alessio Nencioni, Eva Moran, Federico Carbone, Franco Patrone, Giulia Motta, Michele Cea, Valeria Augusti   +6 more
core   +2 more sources